UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000057786 |
|---|---|
| Receipt number | R000066043 |
| Scientific Title | The Efficiency of Cryo or Compression Therapy in the Prevention of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Network Meta-Analysis |
| Date of disclosure of the study information | 2025/05/07 |
| Last modified on | 2025/05/07 10:44:47 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The Efficiency of Cryo or Compression Therapy in the Prevention of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Network Meta-Analysis
Acronym
The Efficiency of Cryo or Compression Therapy in the Prevention of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Network Meta-Analysis
Scientific Title
The Efficiency of Cryo or Compression Therapy in the Prevention of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Network Meta-Analysis
Scientific Title:Acronym
NMA-CIPN
Region
| Japan | Asia(except Japan) | North America |
| South America | Australia | Europe |
| Africa |
Condition
Condition
Chemotherapy-Induced Peripheral Neuropathy
Classification by specialty
| Medicine in general | Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-limiting adverse effect of neurotoxic chemotherapy agents. Despite its prevalence and clinical significance, effective preventive strategies remain limited. This NMA aimed to offer a comprehensive assessment to support clinical decision-making and guide future research in supportive oncology care.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
The primary outcome was the incidence of CIPN.
Key secondary outcomes
Safety
Base
Study type
Others,meta-analysis etc
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
The inclusion criteria comprised RCTs that met the following conditions:1 evaluated the preventive effects of cryotherapy, compression therapy, or cryocompression therapy on CIPN; 2 enrolled adult patients (aged >=8 years) receiving neurotoxic chemotherapy; 3 assessed CIPN occurrence as an outcome of the intervention; and 4 included self-controlled designs, which were considered acceptable.
Key exclusion criteria
Studies were excluded if they met any of the following criteria: (1) the intervention was not intended for prevention; (2) the study was not a randomized controlled trial; or (3) the data were not comparable.
Target sample size
200
Research contact person
Name of lead principal investigator
| 1st name | Hao |
| Middle name | |
| Last name | Chen |
Organization
Teikyo University Hospital
Division name
Department of chemotherapy
Zip code
173-8606
Address
2-11-1 Kaga, Itabashi-ku, Tokyo, Japan
TEL
03-3964-1211
chinksmd@gmail.com
Public contact
Name of contact person
| 1st name | Hao |
| Middle name | |
| Last name | Chen |
Organization
Teikyo University Hospital
Division name
Department of chemotherapy
Zip code
173-8606
Address
2-11-1 Kaga, Itabashi-ku, Tokyo, Japan
TEL
03-3964-1211
Homepage URL
chinsmd@gmail.com
Sponsor or person
Institute
Teikyo University
Institute
Department
Personal name
Funding Source
Organization
Others
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Department of chemotherapy
Address
2-11-1 Kaga, Itabashi-ku, Tokyo, Japan
Tel
03-3964-1211
chinksmd@gmail.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2025 | Year | 05 | Month | 07 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2025 | Year | 04 | Month | 01 | Day |
Date of IRB
Anticipated trial start date
| 2025 | Year | 04 | Month | 09 | Day |
Last follow-up date
| 2025 | Year | 12 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
No additional message
Management information
Registered date
| 2025 | Year | 05 | Month | 07 | Day |
Last modified on
| 2025 | Year | 05 | Month | 07 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066043
